kweetoknie schreef op 19 februari 2019 18:28:
[...]
www.raps.org/news-and-articles/news-a...Onderste alinea:
In a note to health care providers, the agency also said the FDA-recognized Circular of Information for the Use of Human Blood and Blood Components published by AABB lists the following indications for the administration of plasma:“Management of preoperative or bleeding patients who require replacement of multiple plasma coagulation factors (e.g., liver disease, disseminated intravascular coagulation)
Patients undergoing massive transfusion who have clinically significant coagulation deficiencies
Patients taking warfarin who are bleeding or need to undergo an invasive procedure before vitamin K could reverse the warfarin effect or who need only transient reversal of warfarin effect
Transfusion or plasma exchange in patients with thrombotic thrombocytopenic purpura
Transfusion or plasma exchange with selected coagulation factor deficiencies, congenital or acquired, for which no specific coagulation concentrates are available
Management of patients with rare specific plasma protein deficiencies, when recombinant products are unavailable.”Zo duidelijk genoeg?